Viridian Therapeutics Inc.

The sponsor’s programs include investigation of monoclonal antibody approaches targeting the IGF-1 receptor, a pathway closely linked to the underlying biology of TED. This therapeutic area is central to efforts aimed at modifying disease activity and improving clinical outcomes in affected patients.

• IGF-1 receptor targeting
• Monoclonal antibody therapy
• Immune-mediated orbital disease

These studies place emphasis on biologic intervention for a autoimmune-associated ophthalmic disorder.

Viridian Therapeutics explores both subcutaneous and intravenous administration routes for TED-directed therapies, reflecting interest in how different delivery approaches may fit the needs of patients with ongoing disease. The work includes repeated-dosing treatment strategies designed for sustained clinical use.

• Subcutaneous administration
• Intravenous infusion
• Repeat-dose treatment regimens

This therapeutic focus supports evaluation of practical delivery options within ophthalmic immunology.

The sponsor’s clinical research includes assessment of safety, tolerability, and treatment activity in participants with TED. These areas are integral to understanding how investigational therapies perform in patients with variable disease duration and severity.

• Safety assessment
• Tolerability evaluation
• Clinical activity in TED

Research attention is directed toward establishing usable treatment options for a rare endocrine-related eye disorder.

Viridian Therapeutics also supports research pathways that extend access to TED therapies for participants who remain symptomatic after prior treatment. This area of interest includes continued evaluation in previously treated populations and individuals with persistent disease burden.

• Previously treated TED populations
• Non-responder follow-up care
• Persistent disease management

The sponsor’s clinical program remains focused on treatment options for people living with thyroid-associated ophthalmopathy.